PvP Biologics is a California-based biotechnology company with a focus on creating therapies for those with celiac disease, a disorder which inflames an individual's small intestine when gluten in consumed. Its therapeutic product consists of an oral enzyme to alleviate symptoms of the disease, such as pain and internal damage.
The company's product is called TAK-062 (also known as Kuma062) and is a recombinant enzyme that is active under acidic stomach conditions. It was computationally engineered and enzymatically digests gluten in order to reduce the immune-reactive parts of gluten. This digestion occurs before gluten exits the stomach so that the small intestine is less likely to become inflamed, causing the pain and discomfort in celiac patients.
The product completed its Phase 1 clinical trial in early 2020 and is slated to move on to Phase 2 trials. In the Phase 2 trials, efficacy and dose ranges are set to be explored in patients with the disease who also manage a gluten-free diet.
The company was acquired by Takeda, a global research and development pharmaceutical company.
Takeda Acquires Celiac-Focused PvP Biologics in Deal Worth $330 Million
February 26, 2020
Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease
February 26, 2020
- CompanyA company, abbreviated as "Co." within a company name, is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.
- StartupA startup company is an entrepreneurial venture in the initial stage of its operations. Startups are typically young businesses aiming to grow quickly and meet a marketplace need by developing or offering an innovative product, process or service.
- University of WashingtonPublic research university in seattle, washington, united states
- iGEMThe iGEM (International Genetically Engineered Machine) Foundation is a non-profit organization promoting responsible innovation in the field of synthetic biology through competition, collaboration, and community.